Euroopan unioni -
suomi -
EMA (European Medicines Agency)
pravafenix
laboratoires smb s.a. - fenofibraatti, pravastatiinia - dyslipidemiat - lipidimodifioivat aineet - pravafenix on tarkoitettu kohtelu high-sepelvaltimoiden-sydäntautien (chd)-riski aikuisilla mixed dyslipidaemia ominaista korkea triglyseridi ja alhainen hdl-cholesterol (c) jonka ldl-kolesterolitason ovat asianmukaisesti hallinnassa ja jäsenen hoidon pravastatin 40 mg yksinään.
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
fortekor plus
elanco gmbh - benazepril hydrochloride, pimobendan - ace-estäjät, yhdistelmät - koirat - hoitoon kongestiivinen sydämen vajaatoiminta, koska eteis venttiili vajaatoiminta tai laajentuneet kardiomyopatia koirilla.
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
truscient
zoetis belgium sa - dibotermiini alfa - luun morfogeneettiset proteiinit - koirat - osteoinductive agentti käyttää hoidossa pitkän luun murtumia lisänä standardin kirurginen hoito käyttäen avoin murtuma vähentäminen koirilla.
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
chloraprep värillinen 20 mg/ml / 0,70 ml/ml liuos iholle
becton dickinson france sas - chlorhexidine gluconate, isopropyl alcohol - liuos iholle - 20 mg/ml / 0,70 ml/ml - klooriheksidiini
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
chloraprep 20 mg/ml / 0,70 ml/ml liuos iholle
becton dickinson france sas - chlorhexidine gluconate, 2-propanol - liuos iholle - 20 mg/ml / 0,70 ml/ml - klooriheksidiini
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
profast 10 mg/ml injektio/infuusioneste, emulsio
baxter holding b.v. - propofol - injektio/infuusioneste, emulsio - 10 mg/ml - propofoli
Suomi -
suomi -
Fimea (Suomen lääkevirasto)
profast 20 mg/ml injektio/infuusioneste, emulsio
baxter holding b.v. - propofol - injektio/infuusioneste, emulsio - 20 mg/ml - propofoli
Euroopan unioni -
suomi -
EMA (European Medicines Agency)
ecalta
pfizer europe ma eeig - anidulafungiiniryhmässä - kandidiaasi - antimykoottiset aineet systeemiseen käyttöön - invasiivisen kandidiaasin hoitoon aikuisilla ja lapsipotilailla iältään 1 kk - < 18 vuotta.